Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iresa) in human breast and prostate cancer cells

Endocrine-Related Cancer

Volumn 11, Issue 4, 2004, Pages 793-814

  Jones, H E ^a   Goddard, L ^a   Gee, J M W ^a   Hiscox, S ^a   Rubini, M ^b   Barrow, D ^a   Knowlden, J M ^a   Williams, S ^a   Wakeling, A E ^c   Nicholson, R I ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF FERRARA   (Italy)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 BROMO 5 TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; PROTEIN KINASE B; PROTEIN KINASE C DELTA; SOMATOMEDIN C RECEPTOR; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CELL ASSAY; CELL LEVEL; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; MONOLAYER CULTURE; PHENOTYPE; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DNA, COMPLEMENTARY; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GROWTH SUBSTANCES; HUMANS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, IGF TYPE 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 19944427176     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.00799     Document Type: Article

References (61)

1. van Agthoven TT, van Agthoven TL, Portengen H, Foekens JA & Dorssers LC 1992 Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-71 human breast cancer cells. Cancer Research 52 5082-5088.
2. Albini, A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM & McEwan RN 1987 A rapid in vitro assay for quantitating the invasive potential of tumour cells. Cancer Research 47 3239-3245.
3. Alessi DR 2001 Discovery of PDK1, one of the missing links in insulin signal transduction. Biochemical Society Transactions 29 1-14.
4. Barton J, Blackledge G & Wakeling A 2001 Growth factors and their receptors: new targets for prostate cancer therapy. Urology 58 (Suppl 2A) 114-122.
5. Baselga J 2001 Clinical trials of Herceptin (traztuzumab). European Journal of Cancer 37 (Suppl 1) 18-23.
6. Brodt P, Fallavollita L, Khatib A-M, Samani AA & Zhang D 2001 Co-operative regulation of the invasive and metastatic phenotypes by different domains of the type I insulin-like growth factor receptor β subunit. Journal of Biological Chemistry 276 33608-33615.
7. Chakravati A, Loeffler JS & Dyson NJ 2002 Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signalling. Cancer Research 62 200-207.
8. Ciardiello F & Tortora G 2001 A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clinical Cancer Research 7 2958-2970.
9. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR & Tortora G 2000 Antitumour effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clinical Cancer Research 6 2053-2063.
10. Cohen EEW, Rosen F, Dekker A, Bajda C, Stenson K, Shulman KL, Lamont E, Kozloff M & Vokes EE 2002 Phase II study of ZD1839 (Iressa) in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Proceedings of the American Society for Clinical Oncology 21 225a (A899).
11. Connolly JM & Rose DP 1991 Autocrine regulation of DU145 human prostate cancer cell growth by epidermal growth factor-related polypeptides. Prostate 19 173-180.
12. Connolly JM & Rose DP 1994 Regulation of DU145 human prostate cancer cell proliferation by insulin-like growth factors and its interaction with the epidermal growth factor autocrine loop. Prostate 24 167-175.
13. Dekker LV & Parker PJ 1994 Protein kinase C - a question of specificity. Trends in Biochemical Science 19 72-77.
14. Di Marco E, Pierce JH, Fleming TP, Kraus MH, Molloy CJ, Aaronson SA & Di Fiore PP 1989 Autocrine interaction between TGF alpha and EGF-receptor: quantitative requirements for induction of the malignant phenotype. Oncogene 4 831-838.
15. Djakiew D 2000 Dysregulated expression of growth factors and their receptors in the development of prostate cancer. Prostate 42 150-160.
16. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard J-Y, Nishiwaki JF, Vansteenkiste S, Kudo S, Averbuch S, Macleod A, Feyereislova A & Baselga J 2002 Final results from a phase II trial of ZD1839 ('Iressa') for patients with advanced non-small-cell lung cancer (IDEAL 1). Proceedings of the American Society for Clinical Oncology 21 298a (A1188).
17. Gee JMW, Madden T-A, Robertson JF & Nicholson RI 2002 Clinical response and resistance to SERMs. In Endocrine Therapy of Breast Cancer, pp 155-189. Eds JFR Robertson, RI Nicholson & DF Hayes. London: Martin Dunitz Ltd.
18. Geller JA, Galkin AV, Mullen L, Tindell CA, Fox WD, Scher HI & Agus DB 2002 Effects of the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 ('Iressa') on androgen-dependent and androgen-independent human prostate tumour xenografts: growth inhibition and characteristics of resistant tumours. American Association for Cancer Research International Conference Abstract 4971.
19. Genersch E, Schneider DW, Sauer G, Khazaie K, Schuppan D & Lichtner RB 1998 Prevention of EGF-modulated adhesion of tumour cells to matrix proteins by specific EGF receptor inhibition. International Journal of Cancer 75 205-209.
20. Gilmore AP, Valentijn AJ, Wang P, Ranger AM, Bundred N, O'Hare MJ, Wakeling A, Korsmeyer SJ & Streuli CH 2002 Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor. Journal of Biological Chemistry 277 27643-27650.
21. Gonzalez-Larriba J, Giaccone G, van Oosterom AT, Alfonso R, Smit EF, Martens M, Peters GJ, van der Vijgh, Smith R, Fandi A & Averbuch S 2002 ZD1839 (Iressa) in combination with gemcitabine in chemo-naïve patients with advanced solid tumours: final results of a phase I trial. Proceedings of the American Society for Clinical Oncology 21 95a (A376).
22. Goss GD, Stewart DJ, Hirte H, Miller W, Major P, Batist G, Mathews S, Douglas L, Lorimer I & Seymour L 2002 Initial results of part 2 of a phase I/II pharmacokinetic, pharmacodynamic and biological activity study of ZD1839 ('Iressa'): National Cancer Institute of Canada-Clinical trials group IND. 122. Proceedings of the American Society for Clinical Oncology 21 16 (A59).
23. Gullick WJ 2001 The type 1 growth factor receptors and their ligands considered as a complex system. Endocrine-Related Cancer 8 75-82.
24. Hammond LA, Figueroa J, Schwartzberg L, Ochoa L, Hilalgo M, Olivo N, Schwartz G, Smith L, Ochs J & Rowinsky E 2001 Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 ('Iressa') in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in advanced colorectal cancer (ACRC). European Journal of Cancer 37 (Suppl 6) 18a.
25. Harper ME, Goddard L, Glynne-Jones E, Assender J, Dutkowski CM, Barrow D, Dewhurst OL, Wakeling AE & Nicholson RI 2002 Multiple responses to EGF receptor activation and their abrogation by a specific EGF receptor tyrosine kinase receptor. Prostate 51 59-68.
26. Hellawell GO, Turner GDH, Davies DR, Poulsom R, Brewster SF & Macaulay VM 2002 Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Research 62 2942-2950.
27. Herbst RS & Kies MS 2002 ZD1839 (Iressa™) in non-small cell lung carcinoma. The Oncologist 7 (Suppl 4) 9-15.
28. Klein RD & Fischer SM 2002 Black tea polyphenols inhibit IGF-1 induced signalling through Akt in normal prostate epithelial cells and DU145 prostate carcinoma cells. Carcinogenesis 23 217-221.
29. Knowlden J, Gee JM, Bryant S, McClelland RA, Manning DL, Mansel R, Ellis IO, Blamey RW, Robertson JF & Nicholson RI. 1997 Use of reverse transcription-polymerase chain reaction methodology to detect estrogen-regulated gene expression in small breast cancer specimens. Clinical Cancer Research 3 2165-2172.
30. Knowlden J, Hutcheson IR, Jones HE, Madden T, Gee JMW, Harper ME, Barrow D, Wakeling AE & Nicholson RI 2003 Elevated levels of EGFR/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen resistant MCF-7 cells. Endocrinology 144 1032-1044.
31. LeGoode JA, Ziegler WH, Parekh DB, Alessi DR, Cohen P & Parker PJ 1998 Protein kinase C iosotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1. Science 281 2042-2045.
32. Li W, Jiang Y-X, Zhang, Soon L, Flechner L, Kapoor V, Pierce J & Wang L-H 1998 Protein kinase C-δ is an important signalling molecule in insulin-like growth factor I receptor-mediated cell transformation. Molecular and Cell Biology 18 5888-5898.
33. Liu B, Fang M, Lu Y, Mendelsohn J & Fan Z 2001 Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody. Oncogene 20 1913-1922.
34. Long L, Rubin & Brodt P 1998 Enhanced invasion and liver colonization by lung carcinoma cells overexpressing the type I insulin-like growth factor receptor. Experimental Cell Research 238 116-121.
35. Lu Y, Zi X, Zhao Y, Mascarenhas D & Pollak M 2001 Insulin-like growth factor-1 receptor signaling and resistance to trastuzumab (Herceptin). Journal of the National Cancer Institute 93 1852-1857.
36. McClelland RA, Wilson D, Leake R, Finlay P & Nicholson RI 1991 A multicentre study into the reliability of steroid receptor immunocytochemical quantification. British Quality Control Group. European Journal of Cancer 27 711-715.
37. (™). Endocrinology 142 2776-2788.
38. Maile LA & Clemmons DR 2002 Regulation of insulin-like growth factor 1 receptor dephosphorylation by SHPS-1 and the tyrosine phosphatase SHP-2. Journal of Biological Chemistry 277 8955-8960.
39. Miller DL, El-Ashry D, Cheville AL, Liu Y, McLeskey SW & Kern FG 1994 Emergence of MCF7 cells overexpressing a transfected epidermal growth factor receptor (EGFR) under estrogen-depleted conditions: evidence for a role of EGFR in breast cancer growth and progression. Cell Growth and Differentiation 5 1263-1274.
40. Nicholson RI, McClelland RA, Gee JMW, Manning DL, Cannon P, Robertson JFR, Ellis IO & Blamey RW 1994 Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. Breast Cancer Research and Treatment 29 117-125.
41. Nicholson RI, Hutcheson IR, Harper ME, Knowlden JM, Barrow D, McClelland RA, Jones HE, Wakeling AE & Gee JMW 2001 Modulation of epidermal growth factor receptor in endocrine resistant, oestrogen receptor-positive breast cancer. Endocrine-Related Cancer 8 175-182.
42. Nicholson RI, Hutcheson IR, Knowlden JM, Jones HE, Harper ME, Jordan N, Hiscox SE, Barrow D & Gee JM 2004 Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clinical Cancer Research 10 346S-352S.
43. Parrizas M, Gazit A, Levitzki A, Wertheimer E & LeRoith D 1997 Specific inhibition of insulin-like growth factor-1 and insulin receptor tyrosine kinase activity and biological function by tyrphostins. Endocrinology 138 1427-1433.
44. Pollak M 2001 Insulin-like growth factors and prostate cancer. Epidemiology Reviews 23 59-66.
45. Ranson M 2002 ZD1839 (Iressa™): for more than just non-small cell lung carcinoma. The Oncologist 7 (Suppl 4) 16-24.
46. Rocha RL, Hilsenbeck SG, Jackson JG, Van Den Berg CL, Weng C, Lee AV & Yee D 1997 Insulin-like growth factor binding protein 3 and insulin receptor substrate 1 in breast cancer: correlation with clinical parameters and disease-free survival. Clinical Cancer Research 3 103-109.
47. Roudabush F L, Pierce K L, Maudsley S, Khan KD & Luttrell LM 2000 Transactivation of the EGF receptor mediates IGF-1-stimulated she phosphorylation and ERK1/2 activation in COS-7 cells. Journal of Biological Chemistry 275 22583-22589.
48. Rubini M, D'Ambrosio C, Carturan S, Yumet G, Catalano E, Shan S, Huang Z, Ciscuolo M, Pifferi M & Baserga R 1999 Characterization of an antibody that can detect an activated IGF-1 receptor in human cancers. Experimental Cell Research 251 22-32.
49. Sachdev D & Yee D 2001 The IGF system and breast cancer. Endocrine-Related Cancer 8 197-209.
50. Salomon DS, Bradt R, Ciardiello F & Normanno N 1995 Epidermal growth factor-related peptides and their receptors in human malignancies. Critical Reviews in Oncology and Haematology 19 183-232.
51. Shao ZM, Wu J, Shen ZZ & Barsky SH 1998 Genistein inhibits both constitutive and EGF-stimulated invasion in ER-negative human breast cancer cell lines. Anticancer Research 18 1435-1440.
52. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J & Norton L 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancers that over-express HER2. New England Journal of Medicine 344 783-792.
53. Stone KR, Mickey DD, Wunderli H, Mickey GH & Paulson DF 1978 Isolation of a human prostate carcinoma cell line (DU145). International Journal of Cancer 21 274-281.
54. Trump D, Wilding G, Small E et al. 2002 A pilot trial of ZD1839 ('Iressa'), an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with docetaxel and estramustine in patients with hormone refractory prostate cancer (HRPC). Presented at The Annual Meeting of the American Urological Association, Orlando, FL, USA.
55. Turner BC, Haffty BG, Narayanan L, Yuan J, Havre PA, Gumbs AA, Kaplan L, Burgaud JL, Carter D, Baserga R & Glazer PM 1997 IGF-I receptor and cyclin D1 expression influence cellular radiosensitivity and local breast cancer recurrence after lumpectomy and radiation. Cancer Research 57 3079-3083.
56. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ & Gibson KH 2002 ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signalling with potential for cancer therapy. Cancer Research 62 5749-5754.
57. Wang D, Patil S, Li W, Humphrey LE, Brattain MG & Howell GM 2002 Activation of the TGFalpha autocrine loop is downstream of IGF-I receptor activation during mitogenesis in growth factor dependent human colon carcinoma cells. Oncogene 21 2785-2796.
58. Xie H, Turner T, Wang MH, Singh RK, Siegal GP & Wells A 1995 In vitro invasiveness of DU-145 human prostate carcinoma cells is modulated by EGF receptor-mediated signals. Clinical and Experimental Metastasis 13 407-419.
59. Yamakoa T, Ohmori T, Kadofuku T, Noda M, Tsukiyama F, Koizumi K, Nishio K, Saijo N, Kawaguchi T, Adachi M & Kuroki T 2002 Characteristics and resistance mechanism(s) of human non-small-cell lung cancer cell lines with acquired resistance to an epidermal growth factor receptor tyrosine kinase inhibitor. American Association for Cancer Research International Conference Abstract 3886.
60. Yoshinouchi M, Miura M, Gaozza E, Li SW & Baserga R 1993 Basic fibroblast growth factor stimulates DNA synthesis in cells overexpressing the insulin-like growth factor-1 receptor. Molecular Endocrinology 7 1161-1168.
61. Yu H & Rohan T 2000 The role of insulin-like growth factor family in cancer development and progression. Journal of the National Cancer Institute 92 1472-1489.